These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29556960)

  • 1. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP
    Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM
    BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
    BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.
    Tani J; Ito Y; Tatemichi S; Yamakami M; Fukui T; Hatano Y; Kakimoto S; Kotani A; Sugimura A; Mihara K; Yamamoto R; Tanaka N; Minami K; Takahashi K; Hirato T
    PLoS One; 2020; 15(4):e0231830. PubMed ID: 32302352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometric characterisation of darbepoetin alfa biosimilars with C-terminal arginine residues.
    Okano M; Sato M; Kageyama S
    Drug Test Anal; 2016 Nov; 8(11-12):1138-1146. PubMed ID: 27706921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
    Cerutti ML; Pesce A; Bès C; Seigelchifer M
    BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
    Gianoncelli A; Bonini SA; Bertuzzi M; Guarienti M; Vezzoli S; Kumar R; Delbarba A; Mastinu A; Sigala S; Spano P; Pani L; Pecorelli S; Memo M
    BioDrugs; 2015 Aug; 29(4):285-300. PubMed ID: 26334631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers.
    Kim S; Hong T; Ko JW; Huh W; Kim JR
    BioDrugs; 2019 Feb; 33(1):101-112. PubMed ID: 30506495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
    Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
    MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical characterization of Remsima.
    Jung SK; Lee KH; Jeon JW; Lee JW; Kwon BO; Kim YJ; Bae JS; Kim DI; Lee SY; Chang SJ
    MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Assessment of the Effect of Hyper-glycosylation on the Pattern and Kinetics of Degradation of Darbepoetin Alfa using a Stability-Indicating Orthogonal Testing Protocol.
    Moenes EM; Al-Ghobashy MA; Mohamed AA; Salem MY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():405-414. PubMed ID: 29157782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP
    Jeon I; Oh J; Kwon YK; Yoon SH; Cho JY; Jang IJ; Yu KS; Lee S
    Drug Des Devel Ther; 2021; 15():1735-1747. PubMed ID: 33953543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with NESP in anaemic chronic kidney disease patients not on dialysis.
    Lee JH; Ha Chung B; Joo KW; Shin SK; Kim YL; Na KY; Do JY; Park SK; Shin BC; Lee JS; Kim YW; Kim SW; Lee KW; Kang GW; An WS; Shin GT; Han S; Yang CW
    Curr Med Res Opin; 2019 Jun; 35(6):1111-1118. PubMed ID: 30569763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
    Egrie JC; Dwyer E; Browne JK; Hitz A; Lykos MA
    Exp Hematol; 2003 Apr; 31(4):290-9. PubMed ID: 12691916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
    Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
    BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
    Schreiber S; Yamamoto K; Muniz R; Iwura T
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycan analysis of erythropoiesis-stimulating agents.
    Cowper B; Lavén M; Hakkarainen B; Mulugeta E
    J Pharm Biomed Anal; 2020 Feb; 180():113031. PubMed ID: 31838284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS.
    Harazono A; Hashii N; Kuribayashi R; Nakazawa S; Kawasaki N
    J Pharm Biomed Anal; 2013 Sep; 83():65-74. PubMed ID: 23708432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
    Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
    MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Structural, Biological, and Functional Similarity of Biosimilar Granulocyte Colony Stimulating Factor to its Reference Product.
    Bor Tekdemir Z; Seckin AI; Kacar T; Yilmaz E; Bekiroglu S
    Pharm Res; 2020 Oct; 37(11):215. PubMed ID: 33026512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept.
    Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK
    Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.